Oct 04, 2023 8:30am EDT Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy
Sep 20, 2023 8:30am EDT Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity
Aug 24, 2023 8:30am EDT Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib
Aug 22, 2023 8:05am EDT Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders
Aug 21, 2023 8:30am EDT Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib
Aug 17, 2023 8:30am EDT Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro
Aug 14, 2023 4:20pm EDT Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
Aug 07, 2023 8:05am EDT Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023